Bifogade filer
Kurs & Likviditet
Prenumeration
Kalender
2025-02-21 | Bokslutskommuniké 2024 |
2024-11-21 | Kvartalsrapport 2024-Q3 |
2024-08-22 | Kvartalsrapport 2024-Q2 |
2024-05-24 | Ordinarie utdelning ABLI 0.00 SEK |
2024-05-23 | Kvartalsrapport 2024-Q1 |
2024-05-23 | Årsstämma 2024 |
2024-03-26 | Extra Bolagsstämma 2024 |
2024-02-23 | Bokslutskommuniké 2023 |
2023-11-17 | Kvartalsrapport 2023-Q3 |
2023-08-18 | Kvartalsrapport 2023-Q2 |
2023-05-23 | Kvartalsrapport 2023-Q1 |
2023-05-08 | Ordinarie utdelning ABLI 0.00 SEK |
2023-05-05 | Årsstämma 2023 |
2023-03-08 | Extra Bolagsstämma 2022 |
2023-02-24 | Bokslutskommuniké 2022 |
2022-11-22 | Kvartalsrapport 2022-Q3 |
2022-08-19 | Kvartalsrapport 2022-Q2 |
2022-05-31 | Kvartalsrapport 2022-Q1 |
2022-05-20 | Årsstämma 2022 |
2022-04-28 | Ordinarie utdelning ABLI 0.00 SEK |
2022-02-22 | Bokslutskommuniké 2021 |
2021-11-19 | Kvartalsrapport 2021-Q3 |
2021-08-19 | Kvartalsrapport 2021-Q2 |
2021-05-21 | Ordinarie utdelning ABLI 0.00 SEK |
2021-05-20 | Årsstämma 2021 |
2021-05-20 | Kvartalsrapport 2021-Q1 |
2021-04-29 | Extra Bolagsstämma 2021 |
2021-02-19 | Bokslutskommuniké 2020 |
2020-11-20 | Kvartalsrapport 2020-Q3 |
2020-08-21 | Kvartalsrapport 2020-Q2 |
2020-05-22 | Ordinarie utdelning ABLI 0.00 SEK |
2020-05-20 | Årsstämma 2020 |
2020-05-20 | Kvartalsrapport 2020-Q1 |
2020-03-17 | Extra Bolagsstämma 2020 |
2020-02-19 | Bokslutskommuniké 2019 |
2019-11-20 | Kvartalsrapport 2019-Q3 |
2019-08-21 | Kvartalsrapport 2019-Q2 |
2019-05-21 | Kvartalsrapport 2019-Q1 |
2019-04-26 | Ordinarie utdelning ABLI 0.00 SEK |
2019-04-25 | Årsstämma 2019 |
2019-02-28 | Bokslutskommuniké 2018 |
2019-01-17 | Extra Bolagsstämma 2018 |
2018-11-22 | Kvartalsrapport 2018-Q3 |
2018-08-21 | Kvartalsrapport 2018-Q2 |
2018-05-22 | Kvartalsrapport 2018-Q1 |
2018-04-30 | Ordinarie utdelning ABLI 0.00 SEK |
2018-04-27 | Årsstämma 2018 |
2018-02-20 | Bokslutskommuniké 2017 |
2017-11-21 | Kvartalsrapport 2017-Q3 |
2017-08-17 | Kvartalsrapport 2017-Q2 |
2017-05-18 | Kvartalsrapport 2017-Q1 |
2017-04-28 | Ordinarie utdelning ABLI 0.00 SEK |
2017-04-27 | Årsstämma 2017 |
2017-02-21 | Bokslutskommuniké 2016 |
2016-11-22 | Kvartalsrapport 2016-Q3 |
2016-08-18 | Kvartalsrapport 2016-Q2 |
2016-05-31 | Kvartalsrapport 2016-Q1 |
2016-04-29 | Ordinarie utdelning ABLI 0.00 SEK |
2016-04-28 | Årsstämma 2016 |
2016-03-31 | Extra Bolagsstämma 2016 |
2016-02-19 | Bokslutskommuniké 2015 |
2015-11-18 | Kvartalsrapport 2015-Q3 |
2015-08-19 | Kvartalsrapport 2015-Q2 |
2015-05-20 | Kvartalsrapport 2015-Q1 |
2015-03-31 | Ordinarie utdelning ABLI 0.00 SEK |
2015-03-30 | Årsstämma 2015 |
2015-02-18 | Bokslutskommuniké 2014 |
2014-11-19 | Kvartalsrapport 2014-Q3 |
2014-08-20 | Kvartalsrapport 2014-Q2 |
2014-05-12 | Ordinarie utdelning ABLI 0.00 SEK |
2014-05-09 | Kvartalsrapport 2014-Q1 |
2014-05-09 | Årsstämma 2014 |
2014-02-19 | Bokslutskommuniké 2013 |
2014-01-21 | Analytiker möte 2014 |
2013-12-13 | Extra Bolagsstämma 2013 |
2013-11-20 | Kvartalsrapport 2013-Q3 |
2013-08-23 | Kvartalsrapport 2013-Q2 |
2013-05-24 | Kvartalsrapport 2013-Q1 |
2013-03-11 | Ordinarie utdelning ABLI 0.00 SEK |
2013-03-08 | Årsstämma 2013 |
2013-02-05 | Bokslutskommuniké 2012 |
2012-10-15 | Kvartalsrapport 2012-Q3 |
2012-08-21 | Kvartalsrapport 2012-Q2 |
2012-06-11 | Ordinarie utdelning ABLI 0.00 SEK |
2012-06-08 | Årsstämma 2012 |
2012-05-31 | Kvartalsrapport 2012-Q1 |
2012-04-02 | Extra Bolagsstämma 2012 |
2012-02-21 | Bokslutskommuniké 2011 |
2011-11-22 | Kvartalsrapport 2011-Q3 |
2011-08-23 | Kvartalsrapport 2011-Q2 |
2011-06-10 | Årsstämma 2011 |
2011-05-17 | Kvartalsrapport 2011-Q1 |
2011-02-22 | Bokslutskommuniké 2010 |
2010-11-18 | Kvartalsrapport 2010-Q3 |
2010-08-19 | Kvartalsrapport 2010-Q2 |
2010-06-11 | Ordinarie utdelning ABLI 0.00 SEK |
2010-05-20 | Kvartalsrapport 2010-Q1 |
2009-11-19 | Kvartalsrapport 2009-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Endpoint validated enables KL1333 Phase 2/3 study start ⎮ Favorable feedback supports progressing NV354 into Phase 1
Third quarter summary
Important events third quarter (Jul - Sep 2021)
- The study to create a primary mitochondrial disease fatigue endpoint for use in the KL1333 Phase 2/3 study was completed.
- The first chronic toxicology study with KL1333 (six months) was completed.
- Favorable feedback was received from UK pharmaceutical regulators (MHRA) on the NV354 preclinical data package.
Financial information
July-September 2021*
- Net revenues: SEK 85,000 (0,000)
- Other operating income: SEK 0,000 (63,000)
- Loss before tax: SEK 34,854,000 (10,078,000)
- Loss per share: SEK 0.09 (0.03)
- Diluted loss per share: SEK 0.09 (0.03)
January-September 2021*
- Net revenues: SEK 103,000 (105,000)
- Other operating income: SEK 0,000 (45,000)
- Loss before tax: SEK 86,624,000 (46,927,000)
- Loss per share: SEK 0.24 (0.20)
- Diluted loss per share: SEK 0.24 (0.20)
* APM Alternative perfomance measures, see definition on page 20.
The complete Interim report is available for download below and through Abliva's website www.abliva.com
For more information, please contact:
Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com
Abliva AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com
Subscribe to our news: https://abliva.com/posts/news-subscription/
Follow us on LinkedIn: https://www.linkedin.com/company/abliva
Subscribe to our YouTube channel: https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg
Abliva – Delivering mitochondrial health
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD⁺ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, will enter the clinic in 2022. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).